Immunotherapy for Glioma: A compartmental framework for resistance and rational combination design

Abstract

Diffuse gliomas remain among the least responsive solid tumors to immunotherapy despite a compelling rationale for immune surveillance of infiltrative disease. The clinical record—negative phase III checkpoint blockade trials, limited durability of single-antigen vaccines, and impressive but transient responses to adoptive cellular therapy—suggests that failure is rarely attributable to a single mechanism. We propose that glioma immunotherapy resistance is best understood as a compartmental problem. Effective antitumor immunity must traverse a sequence of spatially and functionally distinct compartments: antigen generation and drainage; T-cell priming in deep cervical lymph nodes, cranial bone marrow, or tertiary lymphoid structures; trafficking through vascular and stromal gateways; and effector persistence within a myeloid-rich, metabolically stressed tumor microenvironment. Each therapeutic class acts with a different compartmental center of gravity. Vaccines amplify priming but do not guarantee tumor access or persistence; checkpoint inhibitors require a pre-existing or newly generated tumor-reactive T-cell pool; adoptive cellular therapies bypass priming but remain vulnerable to antigen heterogeneity and local suppression; and oncolytic or innate immune agonists can create in situ inflammatory signals but require compatible trafficking and effector niches. This framework explains why monotherapies have generally underperformed and why effective combinations must be designed to bridge specific blocked compartments rather than simply intensify immune stimulation. It also highlights the importance of tumor state: treatment-naive and treatment-remodeled gliomas may have different dominant immune barriers. Future trials should pair mechanism-matched combinations with biomarkers that report on priming, trafficking, and effector competence.